Related Experiment Videos

Carvedilol prospective randomized cumulative survival (COPERNICUS) trial: carvedilol in severe heart failure

Michael B Fowler1

  • 1Division of Cardiovascular Medicine, Stanford University Medical Center, Stanford, California 94305, USA. mfowler@cvmed.stanford.edu

The American Journal of Cardiology
|May 18, 2004
PubMed

Insights

Carvedilol significantly improved survival for severe heart failure patients in the COPERNICUS trial. This beta-blocker reduced mortality, hospitalizations, and adverse events, showing early benefits.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Severe heart failure poses significant mortality risks.
  • Current therapies often fail to fully manage symptoms or improve survival.

Purpose of the Study:

  • To evaluate the efficacy of carvedilol in patients with severe heart failure.
  • To assess the impact of carvedilol on mortality and hospitalization rates.

Main Methods:

  • The Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial enrolled 2,289 patients.
  • Patients had severe heart failure despite existing therapies and low ejection fraction.
  • Follow-up averaged 10.4 months.

Main Results:

  • Carvedilol reduced all-cause mortality by 34%.
  • Hospitalizations for any cause decreased by 27%, and for heart failure by 40%.
  • Patients reported improved well-being and fewer serious adverse events.

Conclusions:

  • Carvedilol offers substantial survival benefits in severe heart failure.
  • Early benefits were observed, even during dose titration.
  • Carvedilol is a valuable therapeutic option for this patient population.

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...